Urtė Fultinavičiūtė is a journalist who specializes in the field of healthcare and clinical trials. Her work has been featured in various publications including Cigalah Group, Clinical Trials Arena, Medical Device Network, and Pharmaceutical-Technology. Urtė's articles often focus on topics such as the use of artificial intelligence in the pharmaceutical industry, trial diversity goals, and the challenges faced by clinical trial sponsors and regulators.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Urtė focuses predominantly on the healthcare and pharmaceutical industry, with a specific emphasis on clinical trials and advancements in drug development. Her coverage heavily features expert commentary and data citations.
Given her focus, Urtė is likely to be responsive to pitches that offer insights into the latest trends in pharmaceutical research, clinical trial methodologies, or perspectives from experts involved in drug development processes. Topics such as diversity in clinical trials, innovative trial plans for drugs targeting specific conditions like osteoarthritis or mental health issues may align well with her coverage interests.
As Urtė does not specify a geographic focus, it's important to note that she seems interested in global trends within the pharmaceutical and healthcare industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Urtė Fultinavičiūtė
Alkem and Torrent said the tested batches were not manufactured by them, as a recent CDSCO report pinned their drugs as “not of standard quality”. Meanwhile, other firms informed the agency themselves about counterfeit drugs on the market.
By: Urtė Fultinavičiūtė
The US FTC and FDA both received letters from the Senate but with different messaging. One commends for achieved findings and requests a new investigation and another scalds for not doing the assigned job.
By: Urtė Fultinavičiūtė
Lupin has added two ADHD drugs to its Canadian portfolio, while also signing multiple branded deals in other global markets.
By: Urtė Fultinavičiūtė
Along with other approaches, early market entry of generics and biosimilars would barely make a dent in reducing the net prices of retail prescription drugs in the US – but even then, small reductions would add up to billions, reveals the latest CBO calculation.
Backed by AI and former FDA official Janet Woodcock, Every Cure is set to identify approved drugs for patients who don't have treatment options around the world.
By: Urtė Fultinavičiūtė
With marketed European biosimilar rivals already making a dent in Stelara's sales performance, Johnson & Johnson mourns its blockbuster's upcoming loss of exclusivity across the Atlantic Ocean.
By: Urtė Fultinavičiūtė
Celltrion gave updates on several business aspects and reassured its shareholders that the delayed insurance listing for Zymfentra will not affect its set annual sales goal.
By: Urtė Fultinavičiūtė
After a “remarkable performance” in Q2, Samsung Bioepis enjoyed a calm, but still profitable, third quarter.
Respondents to the FDA's questions over biosimilar development did not hold back. So, what is it: product-specific or product class-specific guidance? Or nothing?
By: Urtė Fultinavičiūtė
Also, Finalized FDA Guidances And Regulatory Updates From Canada, Indonesia, And Malaysia Generics Bulletin reviews the latest regulatory developments across the world.
(833) 317-6278 
